PTC Therapeutics (PTCT) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

PTCT Stock Forecast

PTC Therapeutics stock forecast is as follows: an average price target of $46.50 (represents a 10.82% upside from PTCT’s last price of $41.96) and a rating consensus of 'Hold', based on 10 wall street analysts offering a 1-year stock forecast.

PTCT Price Target

The average price target for PTC Therapeutics (PTCT) is $46.50 based on 1-year price targets from 10 Wall Street analysts in the past 3 months, with a price target range of $63.00 to $32.00. This represents a potential 10.82% upside from PTCT's last price of $41.96.

PTCT Analyst Ratings

Hold

According to 10 Wall Street analysts, PTC Therapeutics's rating consensus is 'Hold'. The analyst rating breakdown for PTCT stock is 0 'Strong Buy' (0.00%), 3 'Buy' (30.00%), 5 'Hold' (50.00%), 2 'Sell' (20.00%), and 0 'Strong Sell' (0.00%).

PTC Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Oct 11, 2024	Jeffrey Hung	Morgan Stanley	$45.00	$38.48	16.94%	7.24%
Aug 26, 2024	Colin Bristow	UBS	$47.00	$34.99	34.32%	12.01%
Jul 12, 2024	Jeffrey Hung	Morgan Stanley	$32.00	$33.20	-3.61%	-23.74%
May 20, 2024	Paul Choi	Goldman Sachs	$32.00	$40.12	-20.24%	-23.74%
May 20, 2024	Kelly Shi	Jefferies	$46.00	$39.81	15.55%	9.63%
Apr 26, 2024	Jeffrey Hung	Morgan Stanley	$30.00	$28.57	5.01%	-28.50%
Dec 14, 2022	-	Goldman Sachs	$35.00	$38.94	-10.11%	-16.59%
Jun 23, 2022	Brian Abrahams	RBC Capital	$46.00	$38.29	20.14%	9.63%
Apr 05, 2022	Kristen Kluska	Cantor Fitzgerald	$63.00	$43.64	44.36%	50.14%
Aug 31, 2021	Colin Bristow	UBS	$45.00	$43.65	3.09%	7.24%

Row per page

Go to

The latest PTC Therapeutics stock forecast, released on Oct 11, 2024 by Jeffrey Hung from Morgan Stanley, set a price target of $45.00, which represents a 16.94% increase from the stock price at the time of the forecast ($38.48), and a 7.24% increase from PTCT last price ($41.96).

PTC Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	-	2	6
Avg Price Target	-	$46.00	$38.67
Last Closing Price	$41.96	$41.96	$41.96
Upside/Downside	-100.00%	9.63%	-7.84%

In the current month, the average price target of PTC Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to PTC Therapeutics's last price of $41.96. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 11, 2024	Morgan Stanley	Equal-Weight	Equal-Weight	Hold
Sep 05, 2024	Morgan Stanley	Equal-Weight	Equal-Weight	Hold
Sep 05, 2024	Cowen & Co.	Hold	Hold	Hold
Aug 26, 2024	UBS	-	Buy	Upgrade
Aug 09, 2024	Cowen & Co.	Hold	Hold	Hold
Aug 09, 2024	Barclays	Equal-Weight	Equal-Weight	Hold
Jul 12, 2024	Morgan Stanley	Equal-Weight	Equal-Weight	Hold
Jul 01, 2024	Cantor Fitzgerald	Overweight	Overweight	Hold
Jun 20, 2024	Citigroup	Sell	Sell	Hold
May 20, 2024	Citigroup	Sell	Sell	Hold

Row per page

Go to

PTC Therapeutics's last stock rating was published by Morgan Stanley on Oct 11, 2024. The company gave PTCT a "Equal-Weight" rating, the same as its previous rate.

PTC Therapeutics Financial Forecast

PTC Therapeutics Revenue Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$307.06M	$196.58M	$213.81M	$220.38M	$167.41M	$217.13M	$165.53M	$148.74M	$165.23M	$138.74M	$116.68M	$117.94M	$118.86M	$118.40M
Avg Forecast	$593.37M	$432.67M	$415.21M	$384.84M	$338.77M	$325.09M	$291.25M	$255.97M	$207.71M	$184.48M	$167.54M	$161.41M	$186.00M	$170.59M	$183.28M	$165.49M	$314.96M	$210.23M	$206.99M	$200.52M	$188.38M	$178.52M	$162.12M	$146.91M	$150.83M	$120.44M	$110.13M	$98.82M	$113.35M	$112.21M
High Forecast	$749.94M	$546.84M	$524.77M	$486.38M	$428.16M	$410.87M	$368.09M	$323.51M	$262.51M	$233.15M	$211.75M	$220.73M	$211.03M	$171.33M	$183.28M	$165.63M	$320.66M	$210.23M	$261.61M	$253.42M	$238.09M	$178.52M	$162.12M	$146.91M	$150.83M	$120.44M	$110.13M	$98.82M	$113.35M	$112.21M
Low Forecast	$481.03M	$350.76M	$336.61M	$311.98M	$274.63M	$263.55M	$236.11M	$207.51M	$168.39M	$149.55M	$135.82M	$114.62M	$162.35M	$169.84M	$183.28M	$165.35M	$311.87M	$210.23M	$167.80M	$162.55M	$152.72M	$178.52M	$162.12M	$146.91M	$150.83M	$120.44M	$110.13M	$98.82M	$113.35M	$112.21M
# Analysts	2	2	2	2	2	2	2	2	1	1	1	4	8	4	5	4	8	4	5	4	4	3	4	3	5	4	5	4	9	9
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.97%	0.94%	1.03%	1.10%	0.89%	1.22%	1.02%	1.01%	1.10%	1.15%	1.06%	1.19%	1.05%	1.06%

PTC Therapeutics's average Quarter revenue forecast for Mar 24 based on 4 analysts is $165.49M, with a low forecast of $165.35M, and a high forecast of $165.63M. PTCT's average Quarter revenue forecast represents a -46.11% decrease compared to the company's last Quarter revenue of $307.06M (Dec 23).

PTC Therapeutics EBITDA Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	2	2	2	2	2	2	2	2	1	1	1	4	8	4	5	4	8	4	5	4	4	3	4	3	5	4	5	4	9	9
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-334.83M	$-118.16M	$-209.54M	$-65.84M	$-89.75M	$-77.15M	$-112.74M	$-83.76M	$-97.30M	$-95.11M	$-80.34M	$-95.44M	$-25.03M	$-14.55M
Avg Forecast	$-353.32M	$-257.63M	$-247.24M	$-229.15M	$-201.72M	$-193.57M	$-173.42M	$-152.42M	$-123.68M	$-109.85M	$-99.76M	$-96.11M	$-110.75M	$-101.57M	$-109.13M	$-71.60M	$-187.54M	$-125.18M	$-123.25M	$-65.10M	$-81.57M	$-83.34M	$-75.68M	$-59.18M	$-70.41M	$-56.23M	$-51.41M	$-75.22M	$-52.92M	$-52.38M
High Forecast	$-286.43M	$-208.86M	$-200.43M	$-185.77M	$-163.53M	$-156.93M	$-140.59M	$-123.56M	$-100.26M	$-89.05M	$-80.87M	$-68.25M	$-96.67M	$-101.13M	$-109.13M	$-57.28M	$-185.70M	$-125.18M	$-99.92M	$-52.08M	$-65.26M	$-83.34M	$-75.68M	$-47.34M	$-70.41M	$-56.23M	$-51.41M	$-60.17M	$-52.92M	$-52.38M
Low Forecast	$-446.54M	$-325.61M	$-312.47M	$-289.61M	$-254.94M	$-244.65M	$-219.18M	$-192.63M	$-156.31M	$-138.83M	$-126.08M	$-131.43M	$-125.65M	$-102.02M	$-109.13M	$-85.93M	$-190.93M	$-125.18M	$-155.77M	$-78.11M	$-97.89M	$-83.34M	$-75.68M	$-71.01M	$-70.41M	$-56.23M	$-51.41M	$-90.26M	$-52.92M	$-52.38M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.79%	0.94%	1.70%	1.01%	1.10%	0.93%	1.49%	1.42%	1.38%	1.69%	1.56%	1.27%	0.47%	0.28%

undefined analysts predict PTCT's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than PTC Therapeutics's previous annual EBITDA (undefined) of $NaN.

PTC Therapeutics Net Income Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	2	2	2	2	2	2	2	2	1	1	1	4	8	4	5	4	8	4	5	4	4	3	4	3	5	4	5	4	9	9
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-155.79M	$-132.97M	$-198.88M	$-138.96M	$-170.89M	$-109.31M	$-152.09M	$-126.73M	$-143.26M	$-133.62M	$-118.37M	$-128.64M	$-74.35M	$-69.69M
Avg Forecast	$217.45M	$50.66M	$52.64M	$45.99M	$12.95M	$5.41M	$-9.22M	$-26.09M	$-33.40M	$-57.31M	$-64.93M	$-68.35M	$-90.26M	$-117.01M	$-86.15M	$-125.92M	$-10.63M	$-81.92M	$-124.72M	$-114.47M	$-120.12M	$-98.45M	$-104.97M	$-104.07M	$-128.84M	$-127.11M	$-139.08M	$-101.38M	$-70.35M	$-63.15M
High Forecast	$292.04M	$68.04M	$70.70M	$61.77M	$17.39M	$7.26M	$-6.95M	$-19.67M	$-25.18M	$-43.21M	$-48.95M	$22.02M	$-56.05M	$-88.21M	$-64.95M	$-100.74M	$40.33M	$-61.76M	$-94.03M	$-91.58M	$-96.09M	$-98.45M	$-104.97M	$-83.25M	$-128.84M	$-127.11M	$-139.08M	$-81.10M	$-70.35M	$-63.15M
Low Forecast	$163.93M	$38.19M	$39.68M	$34.67M	$9.76M	$4.08M	$-12.39M	$-35.03M	$-44.86M	$-76.97M	$-87.20M	$-120.75M	$-117.19M	$-157.14M	$-115.70M	$-151.10M	$-32.26M	$-110.03M	$-167.50M	$-137.37M	$-144.14M	$-98.45M	$-104.97M	$-124.88M	$-128.84M	$-127.11M	$-139.08M	$-121.66M	$-70.35M	$-63.15M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	14.65%	1.62%	1.59%	1.21%	1.42%	1.11%	1.45%	1.22%	1.11%	1.05%	0.85%	1.27%	1.06%	1.10%

PTC Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. PTCT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

PTC Therapeutics SG&A Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	2	2	2	2	2	2	2	2	1	1	1	4	8	4	5	4	8	4	5	4	4	3	4	3	5	4	5	4	9	9
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$76.29M	$80.89M	$88.45M	$86.91M	$92.72M	$80.12M	$79.89M	$73.27M	$86.55M	$69.25M	$68.88M	$61.09M	$75.46M	$57.84M
Avg Forecast	$315.12M	$229.78M	$220.51M	$204.38M	$179.91M	$172.65M	$154.67M	$135.94M	$110.31M	$97.97M	$88.98M	$85.72M	$98.78M	$90.59M	$97.34M	$72.81M	$167.26M	$111.65M	$109.93M	$66.19M	$72.56M	$94.80M	$86.10M	$60.17M	$80.10M	$63.96M	$58.49M	$48.15M	$60.20M	$59.59M
High Forecast	$398.27M	$290.41M	$278.69M	$258.30M	$227.38M	$218.20M	$195.48M	$171.81M	$139.41M	$123.82M	$112.45M	$117.23M	$112.07M	$90.99M	$97.34M	$87.37M	$170.29M	$111.65M	$138.93M	$79.42M	$87.08M	$94.80M	$86.10M	$72.20M	$80.10M	$63.96M	$58.49M	$57.78M	$60.20M	$59.59M
Low Forecast	$255.46M	$186.28M	$178.76M	$165.68M	$145.85M	$139.96M	$125.39M	$110.20M	$89.42M	$79.42M	$72.13M	$60.87M	$86.22M	$90.20M	$97.34M	$58.24M	$165.62M	$111.65M	$89.12M	$52.95M	$58.05M	$94.80M	$86.10M	$48.14M	$80.10M	$63.96M	$58.49M	$38.52M	$60.20M	$59.59M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.46%	0.72%	0.80%	1.31%	1.28%	0.85%	0.93%	1.22%	1.08%	1.08%	1.18%	1.27%	1.25%	0.97%

PTC Therapeutics's average Quarter SG&A projection for Mar 24 is $72.81M, based on 4 Wall Street analysts, with a range of $58.24M to $87.37M. The forecast indicates a -4.57% fall compared to PTCT last annual SG&A of $76.29M (Dec 23).

PTC Therapeutics EPS Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	2	2	2	2	2	2	2	2	1	1	1	4	8	4	5	4	8	4	5	4	4	3	4	3	5	4	5	4	9	9
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-0.00	$-1.76	$-0.00	$-1.88	$-2.35	$-1.53	$-2.13	$-1.78	$-2.03	$-1.89	$-1.68	$-1.83	$-1.10	$-1.03
Avg Forecast	$2.83	$0.66	$0.68	$0.60	$0.17	$0.07	$-0.12	$-0.34	$-0.43	$-0.75	$-0.84	$-0.89	$-1.17	$-1.52	$-1.12	$-1.27	$-0.14	$-1.06	$-1.62	$-1.53	$-1.59	$-1.28	$-1.37	$-1.51	$-1.68	$-1.66	$-1.81	$-1.54	$-0.92	$-0.82
High Forecast	$3.80	$0.88	$0.92	$0.80	$0.23	$0.09	$-0.09	$-0.26	$-0.33	$-0.56	$-0.64	$0.29	$-0.73	$-1.15	$-0.84	$-0.96	$0.52	$-0.80	$-1.22	$-1.16	$-1.20	$-1.28	$-1.37	$-1.51	$-1.68	$-1.66	$-1.81	$-1.54	$-0.92	$-0.82
Low Forecast	$2.13	$0.50	$0.52	$0.45	$0.13	$0.05	$-0.16	$-0.46	$-0.58	$-1.00	$-1.13	$-1.57	$-1.52	$-2.04	$-1.50	$-1.71	$-0.42	$-1.43	$-2.18	$-2.06	$-2.13	$-1.28	$-1.37	$-1.51	$-1.68	$-1.66	$-1.81	$-1.54	$-0.92	$-0.82
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.02%	1.65%	0.00%	1.23%	1.48%	1.19%	1.56%	1.18%	1.21%	1.14%	0.93%	1.18%	1.20%	1.25%

According to undefined Wall Street analysts, PTC Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to PTCT previous annual EPS of $NaN (undefined).

PTC Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
HEPA	Hepion Pharmaceuticals	$0.69	$70.00	10044.93%	Buy
IOVA	Iovance Biotherapeutics	$8.14	$21.00	157.99%	Buy
VKTX	Viking Therapeutics	$51.53	$102.40	98.72%	Buy
SRPT	Sarepta Therapeutics	$110.86	$169.06	52.50%	Buy
BPMC	Blueprint Medicines	$94.81	$109.71	15.72%	Buy
PTCT	PTC Therapeutics	$41.96	$46.50	10.82%	Hold
KRYS	Krystal Biotech	$178.10	$191.00	7.24%	Buy
MDGL	Madrigal Pharmaceuticals	$317.09	$315.75	-0.42%	Buy

PTCT Forecast FAQ

Is PTC Therapeutics a good buy?

No, according to 10 Wall Street analysts, PTC Therapeutics (PTCT) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 30.00% of PTCT's total ratings.

What is PTCT's price target?

PTC Therapeutics (PTCT) average price target is $46.5 with a range of $32 to $63, implying a 10.82% from its last price of $41.96. The data is based on 10 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will PTC Therapeutics stock go up soon?

According to Wall Street analysts' prediction for PTCT stock, the company can go up by 10.82% (from the last price of $41.96 to the average price target of $46.5), up by 50.14% based on the highest stock price target, and down by -23.74% based on the lowest stock price target.

Can PTC Therapeutics stock reach $60?

PTCT's highest twelve months analyst stock price target of $63 supports the claim that PTC Therapeutics can reach $60 in the near future.

What are PTC Therapeutics's analysts' financial forecasts?

PTC Therapeutics's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $1.21B (high $1.53B, low $981.8M), average EBITDA is $-721M (high $-585M, low $-911M), average net income is $-16.954M (high $-1.968M, low $-33.584M), average SG&A $643.17M (high $812.87M, low $521.4M), and average EPS is $-0.22 (high $-0.0256, low $-0.437). PTCT's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $1.83B (high $2.31B, low $1.48B), average EBITDA is $-1.087B (high $-881M, low $-1.374B), average net income is $366.75M (high $492.55M, low $276.49M), average SG&A $969.78M (high $1.23B, low $786.19M), and average EPS is $4.77 (high $6.4, low $3.59).

Did the PTCT's actual financial results beat the analysts' financial forecasts?

Based on PTC Therapeutics's last annual report (Dec 2023), the company's revenue was $937.82M, beating the average analysts forecast of $932.7M by 0.55%. Apple's EBITDA was $-440M, missing the average prediction of $-501M by -12.29%. The company's net income was $-627M, beating the average estimation of $-332M by 88.88%. Apple's SG&A was $332.54M, missing the average forecast of $455.03M by -26.92%. Lastly, the company's EPS was $-0.0084, missing the average prediction of $-4.359 by -99.81%. In terms of the last quarterly report (Dec 2023), PTC Therapeutics's revenue was $307.06M, missing the average analysts' forecast of $314.96M by -2.51%. The company's EBITDA was $-335M, beating the average prediction of $-188M by 78.54%. PTC Therapeutics's net income was $-156M, beating the average estimation of $-10.632M by 1365.33%. The company's SG&A was $76.29M, missing the average forecast of $167.26M by -54.39%. Lastly, the company's EPS was $-0.0021, missing the average prediction of $-0.138 by -98.48%